These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Zen M; Iaccarino L; Gatto M; Bettio S; Nalotto L; Ghirardello A; Punzi L; Doria A Ann Rheum Dis; 2015 Dec; 74(12):2117-22. PubMed ID: 26223434 [TBL] [Abstract][Full Text] [Related]
9. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125 [TBL] [Abstract][Full Text] [Related]
13. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. Petri M; Magder LS Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142 [TBL] [Abstract][Full Text] [Related]
15. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Formiga F; Moga I; Pac M; Mitjavila F; Rivera A; Pujol R Rheumatology (Oxford); 1999 Aug; 38(8):724-7. PubMed ID: 10501419 [TBL] [Abstract][Full Text] [Related]
17. Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Fasano S; Margiotta DPE; Pierro L; Navarini L; Riccardi A; Afeltra A; Valentini G Clin Rheumatol; 2019 Feb; 38(2):457-463. PubMed ID: 30194649 [TBL] [Abstract][Full Text] [Related]
18. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K Rheumatology (Oxford); 2019 Dec; 58(12):2170-2176. PubMed ID: 31157891 [TBL] [Abstract][Full Text] [Related]
19. Factors associated with remission in patients with systemic lupus erythematosus: new insights into a desirable state. Romo-Tena J; la Garza RR; Bartnicki-Navarrete I; Alcocer-Varela J; Gómez-Martin D Clin Rheumatol; 2018 Nov; 37(11):3033-3042. PubMed ID: 30056524 [TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. Tani C; Elefante E; Signorini V; Zucchi D; Lorenzoni V; Carli L; Stagnaro C; Ferro F; Mosca M RMD Open; 2019; 5(2):e000916. PubMed ID: 31275608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]